IGM Biosciences, Inc. Deferred Revenue
IGM Biosciences, Inc. had Deferred Revenue of $0 as of 2025-06-30, per its 10-Q filed 2025-07-31.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2025-07-31
- 2025-06-30: Deferred Revenue $0.00.
- 2025-03-31: Deferred Revenue $143.62M.
- 2024-12-31: Deferred Revenue $144.12M.
- 2024-09-30: Deferred Revenue $144.53M.
| Period end | Deferred Revenue |
|---|---|
| 2025-06-30 | $0.00 10-Q · filed 2025-07-31 |
| 2025-03-31 | $143.62M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $144.12M 10-Q · filed 2025-07-31 |
| 2024-09-30 | $144.53M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $145.05M 10-Q · filed 2025-07-31 |
| 2024-03-31 | $146.30M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $146.80M 10-Q · filed 2025-07-31 |
| 2023-09-30 | $147.45M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $147.96M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $148.41M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $148.93M 10-K · filed 2025-03-06 |
| 2022-09-30 | $149.30M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $149.63M 10-Q · filed 2023-08-03 |
| 2021-12-31 | $0.00 10-K · filed 2024-03-07 |